June 2007 Cover
|
 |
Merck has announced good results from two phase-three clinical trials of its HIV drug candidate Isentress, formerly known as MK-0518.
In the studies, researchers paired the new drug with a drug the patients had already been using; control-group patients received a placebo and a treatment they were already using.
The trials focused on patients who had failed antiretroviral therapies and were resistant to at least one drug in three antiretroviral classes. Isentress was found to reduce HIV loads in more than 75 percent of patients in
both trials.
Merck said it plans to apply for Food and Drug Administration approval of the new treatment in the second quarter of 2007.
from the Associated Press
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
